Cited by 55Mitochondrial Function and PathologyMetabolism, Diabetes, and CancerAdipose Tissue and Metabolism

Antidiabetic and cardiovascular beneficial effects of a liver-localized mitochondrial uncoupler

Open access
Kanemoto, Naohide, Okamoto, Takashi, Tanabe, Koji, Shimada, Takahiro, Minoshima, Hitomi, Hidoh, Yuya, Aoyama, Masashi, Ban, Takashi +5 more·2019·Nature Communications

Abstract

Inducing mitochondrial uncoupling (mUncoupling) is an attractive therapeutic strategy for treating metabolic diseases because it leads to calorie-wasting by reducing the efficiency of oxidative phosphorylation (OXPHOS) in mitochondria. Here we report a safe mUncoupler, OPC-163493, which has unique pharmacokinetic characteristics. OPC-163493 shows a good bioavailability upon oral administration and primarily distributed to specific organs: the liver and kidneys, avoiding systemic toxicities. It exhibits insulin-independent antidiabetic effects in multiple animal models of type I and type II diabetes and antisteatotic effects in fatty liver models. These beneficial effects can be explained by the improvement of glucose metabolism and enhancement of energy expenditure by OPC-163493 in the liver. Moreover, OPC-163493 treatment lowered blood pressure, extended survival, and improved renal function in the rat model of stroke/hypertension, possibly by enhancing NO bioavailability in blood vessels and reducing mitochondrial ROS production. OPC-163493 is a liver-localized/targeted mUncoupler that ameliorates various complications of diabetes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-019-09911-6

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • OPC-163493 decreases hepatic steatosis, lowers fasting glucose and HbA1c, increases nitric oxide bioavailability, and reduces vascular oxidative stress in multiple rodent models of metabolic syndrome.

    “Kanemoto and colleagues272 described a liver-localized mitochondrial uncoupler, OPC-163493, which was shown to have various benefits in multiple rodent models of the metabolic syndrome, such as decreasing hepatic steatosis and lowering fasting levels of glucose and HbA1c, as well as increasing nitric oxide bioavailability and reducing oxidative stress in blood vessels.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Kanemoto, N., Okamoto, T., Tanabe, K., Shimada, T., Minoshima, H., Hidoh, Y., Aoyama, M., Ban, T., Kobayashi, Y., Ando, H., Inoue, Y., Itotani, M., & Sato, S.
Affiliations
Otsuka (Japan) (JP)
Corresponding author
Kanemoto, Naohide
Venue
Nature Communications
Published
2019-05-15
Volume
10
Issue
1
Pages
2172-2172
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2945783425
Cited by
55
References
68
Citations by year
2026: 4 · 2025: 5 · 2024: 7 · 2023: 8 · 2022: 6 · 2021: 11 · 2020: 10 · 2019: 3
FWCI
2.48
Type
journal article
Language
en
Open access
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
Otsuka Pharmaceutical
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Physiology › Adipose Tissue and Metabolism
Keywords
mitochondrial uncoupling, antidiabetic effect, type 1 diabetes, type 2 diabetes, hepatic steatosis, liver-targeted drug delivery, oral bioavailability, energy expenditure, glucose metabolism, hypertension, stroke, blood pressure, nitric oxide bioavailability, mitochondrial reactive oxygen species, renal function, pharmacokinetics
MeSH terms
Administration, Oral, Animals, Blood Pressure, Cricetulus, Diabetes Mellitus, Disease Models, Animal, Fatty Liver, Female, Humans, Hypertension, Hypoglycemic Agents, Kidney, Liver, Male, Mitochondria, Oxidative Phosphorylation, Uncoupling Agents, Survival Analysis, CHO Cells, Rats, Sprague-Dawley, Stroke, Mice, Rats, Hep G2 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review